AGTC

AGTC is a clinical-stage biotechnology company dedicated to revolutionizing patient lives through its groundbreaking gene therapy platform. Specializing in ophthalmology, the company is focused on addressing inherited orphan diseases of the eye caused by mutations in single genes that significantly impair visual function and presently lack effective treatments. AGTC's product pipeline encompasses six ophthalmology development programs across five targets, including X-linked retinoschisis, X-linked retinitis pigmentosa, achromatopsia, wet age-related macular degeneration, and blue cone monochromacy, along with two non-ophthalmology programs.

AGTC is also actively exploring genetic defects leading to deafness and anticipates advancing several product candidates into development in the coming years. Founded in 1999, AGTC employs a highly targeted approach in selecting and designing its product candidates, focusing on indications with high unmet medical needs, clinical feasibility, and commercial potential. The company boasts a remarkable intellectual property portfolio and extensive expertise in gene therapy product design and manufacturing.

Recently, AGTC secured a $10.00M Post-IPO Equity investment on 12 July 2022. The company, headquartered in the United States, continues to attract interest and support for its visionary science in life-changing cures.